Recruiting

Fulvic Acid

Sponsor:

Arizona State University

Code:

NCT07927283

Conditions

Metabolic Syndrome

Eligibility Criteria

Sex: All

Age: 18 - 65

Healthy Volunteers: Not accepted

Interventions

fulvic acid

fulvic acid

Placebo

Study Details

Brief summary:

Fulvic acid is a naturally occurring compound derived from the decomposition of organic matter in soil over long periods. Fulvic acid complexes, such as MLG-50 (MLG-50® Mineral Logic, Kalamazoo, Michigan), offer a highly concentrated, water-soluble form of fulvic acid that contains over 70 trace minerals and elements. Our preclinical studies have found that a soil derived organic mineral complex rich in fulvic acid prevented the high fat diet induced hyperglycemia, endothelial dysfunction, liver injury, endotoxemia, and gut dysbiosis induced by high-fat feeding in rats. We propose to examine the efficacy of fulvic acid (both 50 mg and 100 mg daily for 12 weeks) in the mitigation of symptoms related to metabolic syndrome.

Conditions

Metabolic Syndrome

Study ID

NCT07927283

Start date

Nov 6, 2026

Status verified date

Nov, 2026

Completion date

Nov 15, 2027

Anticipated

Primary completion date

Nov 15, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18 - 65

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • metabolic syndrome or prediabetes

Exclusion Criteria:

  • pregnant or nursing
  • multiple medications to treat obesity, heart disease, thyroid conditions, cancer
  • smokers
  • competing athletes
  • vegetarians

Study Design

Enrollment

60 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Other

Interventions and Outcome Measures

Arms

experimental: Fulvic acid 50

50 mg

experimental: Fulvic acid 100

100 mg

placebo comparator: Placebo

cornstarch

Interventions

fulvic acid

50 mg

fulvic acid

100 mg

Placebo

cornstarch

Primary outcome measure

  • girth [ Time Frame: from enrollment to 6 week and to 12 week ]
  • hypertension [ Time Frame: from enrollment to 6 week and to 12 week ]
  • hyperglycemia [ Time Frame: from enrollment to 6 week and to 12 week ]
  • hypertriglyceridemia [ Time Frame: from enrollment to 6 week and to 12 week ]
  • cholesterol [ Time Frame: from enrollment to 6 week and to 12 week ]

Central Contacts and Locations

Central contacts

Carol Johnston, PhD

6024963463carol.johnston@asu.edu

Karen Sweazea, PhD

4809656025karen.sweazea@asu.edu

Locations

PBC 850 N 5th Street

Recruiting

Phoenix, Arizona, United States, 85004

Contacts

Carol Johnston, PhD

6024962539carol.johnston@asu.edu

Karen Sweazea, PhD

4809656025karen.sweazea@asu.edu

More Information

Sponsor

Arizona State University

Last update posted

Nov 10, 2026

Last verified

Nov, 2026

Keywords

  • Fulvic acid
  • Metabolic syndrome
  • Pre-diabetes

Trial information was received from ClinicalTrials.gov and was last updated on 2026-11-11. This information was provided to ClinicalTrials.gov by Arizona State University on 2026-11-10. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.